Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - sertraline hydrochloride, quantity: 56 mg (equivalent: sertraline, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; sodium starch glycollate; hyprolose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400; indigo carmine aluminium lake - children and adolescents,sertraline generichealth is indicated for the treatment of children (aged 6 years of age and older) and adolescents with ocd.,adults,sertraline generichealth is indicated for the treatment of major depression, obsessive compulsive disorder (ocd) and panic disorder.,sertraline generichealth is indicated for the treatment of social phobia (social anxiety disorder) and the prevention of its relapse.,sertraline generichealth is indicated for the treatment of premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metformin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paracetamol, quantity: 325 mg; tramadol hydrochloride, quantity: 37.5 mg - tablet, film coated - excipient ingredients: powdered cellulose; magnesium stearate; macrogol 6000; sodium starch glycollate type a; titanium dioxide; hypromellose; pregelatinised maize starch; purified talc; iron oxide yellow; lactose monohydrate; maize starch; propylene glycol - zaldiar is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride hemihydrate, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of:,? major depression and for the prevention of relapse of depressive symptoms;,? obsessive compulsive disorder and for the prevention of relapse of ocd;,? panic disorder and for the prevention of relapse of panic disorder;,? social anxiety disorder/social phobia; and,? generalised anxiety disorder;,? posttraumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - paroxetine hydrochloride hemihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - ciprofloxacin hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - ciprofloxacin hydrochloride, quantity: 294.586 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.